Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
104 hedge funds and large institutions have $115M invested in Aratana Therapeutics, Inc. in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 30 reducing their positions, and 27 closing their positions.
295% more call options, than puts
Call options by funds: $387K | Put options by funds: $98K
13% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 30
10% less funds holding
Funds holding: 115 → 104 (-11)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
41% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 27
44% less capital invested
Capital invested by funds: $206M → $115M (-$90.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$13.8M |
| 2 |
JG
Jefferies Group
New York
|
+$6.5M |
| 3 |
Impax Asset Management Group
London,
United Kingdom
|
+$4.04M |
| 4 |
MCM
Moore Capital Management
New York
|
+$1.3M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$33.9M |
| 2 |
EC
Engaged Capital
Newport Beach,
California
|
-$4.64M |
| 3 |
Millennium Management
New York
|
-$2.28M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
-$2.06M |
| 5 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
-$1.88M |
PETX Hedge Fund Activity: Q1 2019 in Review
104 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q1 2019, worth a combined $115M — down 44% from $206M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of PETX and 16 opened new positions — a net loss of 11 holders — while 30 trimmed existing stakes and 34 added.
The largest buyer was Broadfin Capital, adding an estimated $13.8M. The largest seller was Franklin Resources, exiting entirely with an estimated $33.9M sold.
- 104 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q1 2019, down from 115 in Q4 2018.
- Funds reported $115M of Aratana Therapeutics, Inc. stock for Q1 2019, down 44% quarter-over-quarter.
- 16 funds opened new Aratana Therapeutics, Inc. positions in Q1 2019 and 27 closed out, a net change of -11 holders.
- The largest Aratana Therapeutics, Inc. buyer in Q1 2019 was Broadfin Capital, an estimated $13.8M added.
- The largest Aratana Therapeutics, Inc. seller in Q1 2019 was Franklin Resources, an estimated $33.9M sold.
Based on aggregated 13F filings for Q1 2019.